Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07569926 · ClinicalTrials.gov registry record · Phase 4
Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence
A Phase 4 study, sponsored by Blue Earth Diagnostics.
- Not yet
- Registry status
- Phase 4
- Development phase
- 142
- Enrollment target
NCT07569926 is a Phase 4 study that has not yet begun recruiting, run by Blue Earth Diagnostics. The registered enrollment target is 142 participants.
The verdict
NCT07569926, a Phase 4 study, has not yet begun recruiting, sponsored by Blue Earth Diagnostics.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 142 participants
- Enrollment target
Study Summary
The impact of fluciclovine (18F) PET on the management of participants with prostate cancer following negative or equivocal PSMA PET Imaging at the time of biochemical recurrence
Interventions
- DRUG fluciclovine (18F)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 142 participants |
| Start Date | 2026-06-01 |
| Est. Completion | 2032-12-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07569926
The ClinicalTrials.gov registry entry for NCT07569926 describes a study currently listed as not yet recruiting, categorized as Phase 4. The registered enrollment target is 142 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Blue Earth Diagnostics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which fluciclovine (18F) is the first listed.
NCT07569926 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07569926 about?
NCT07569926 is a clinical study titled "Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence". The impact of fluciclovine (18F) PET on the management of participants with prostate cancer following negative or equivocal PSMA PET Imaging at the time of biochemical recurrence
What is the current status of trial NCT07569926?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 142 participants. The study started on 2026-06-01. Estimated completion is 2032-12-31.
What interventions are being tested in trial NCT07569926?
The interventions under investigation include: fluciclovine (18F) (DRUG).
Who is sponsoring clinical trial NCT07569926?
This trial is sponsored by Blue Earth Diagnostics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.